About
Technology
Issues
FAQ
Links
Official Page
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.